Tesamorelin
Also known as: Egrifta, TH9507
An FDA-approved GHRH analog for reducing visceral adipose tissue.
Overview
Tesamorelin is a synthetic GHRH analog approved for treatment of HIV-associated lipodystrophy. It specifically targets visceral fat reduction while stimulating natural GH pulsatility.
Mechanism of Action
Binds pituitary GHRH receptors to stimulate physiological GH release. The resulting GH and IGF-1 elevation promotes lipolysis, particularly in visceral adipose tissue.
Pharmacokinetics
Peak GH release within 30-60 minutes. Effects on body composition require weeks of treatment. Half-life approximately 26 minutes.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Standard
2 mg
Once daily
24+ weeks
FDA-approved dosing
Stacking Recommendations
Peptides that may be combined based on complementary mechanisms in research settings.
Research Areas
Key Research Findings
- 1FDA-approved for HIV lipodystrophy with significant VAT reduction
- 2Reduced liver fat in NAFLD studies
- 3Potential cognitive benefits in aging populations
- 4Maintains pulsatile GH pattern
Side Effects & Contraindications
Reported Side Effects
- Injection site reactions
- Joint pain
- Peripheral edema
- Paresthesia
Contraindications
- Active malignancy
- Disrupted hypothalamic-pituitary axis
- Pregnancy
Safety Considerations
May cause joint pain, peripheral edema. Monitor glucose in diabetic patients. Contraindicated in active malignancy.
Storage Requirements
Refrigerate at 2-8C
Scientific References
- 1